Skip to main content

Multiple Myeloma

Featured Article
According to study authors, “Our findings highlight the importance of considering indirect costs alongside efficacy, safety, and direct costs during the treatment decision-making process.”
Patients recently diagnosed with multiple myeloma are incurring greater healthcare costs compared with patients diagnosed just a few years earlier, however, those additional dollars spent coincide…


Ravi Vij, MD, MBA, from Washington University School of Medicine in St Louis, discusses his recent study findings that evaluated treatment sequences among patients with relapsed or refractory multiple myeloma after failure of daratumumab-based…
Back to Top